Life Sciences & MOB: Resilient Demand Amidst Rate Volatility
By Majid Radaei, RadCRE · · Industry Insights
Life sciences and medical office building (MOB) investments continue to defy broader CRE headwinds, with Q4 2025 seeing $8.5B in transactions, driven by demographic shifts and R&D funding.
Steady Outperformance of Healthcare and Life Sciences Real Estate
The commercial real estate landscape in late 2025 and early 2026 continues to be shaped by elevated interest rates and persistent — albeit moderating — inflation. Within this climate, the life sciences and medical office building (MOB) sectors have demonstrated remarkable resilience, attracting significant investor capital due to their defensive characteristics and strong underlying demand drivers.
According to recent reports from CBRE and Real Capital Analytics (RCA), investment volume in these specialized sectors has remained robust. In Q4 2025 alone, the combined transaction volume for life sciences and MOB properties topped an estimated $8.5 billion, a notable figure given the broader slowdown in other asset classes. This sustained demand is underpinned by an aging population, advances in medical technology, and substantial R&D funding, particularly in the pharmaceutical and biotech industries.
Key Drivers and Market Activity
Demographic tailwinds are a primary catalyst for MOBs. The U.S. population aged 65 and older is projected to nearly double by 2060, significantly increasing the need for outpatient facilities and specialized healthcare services. This predictability of demand makes MOBs attractive to institutional investors seeking stable, long-term income streams. For instance, Ventas, a leading healthcare REIT, recently announced an acquisition of a portfolio of core MOBs for approximately $550 million in Q1 2026, targeting an initial cap rate in the low 6% range, showcasing continued appetite for quality assets.
The life sciences sector, while more cyclical, benefits from consistent innovation and a growing pipeline of biotechnological breakthroughs. Major hubs such as Boston-Cambridge, the San Francisco Bay Area, and San Diego continue to command premium rents and low vacancy rates. In Q4 2025, CoStar reported vacancy rates for lab space in Cambridge, MA, hovering around 4.5%, with average asking rents reaching upward of $105 per square foot (NNN) for prime space. Recent noteworthy transactions include BioMed Realty's continued expansion in the Boston market, with the acquisition of a development site for a new research facility in early 2026, further solidifying the sector's growth trajectory.
Capital Markets Nuances
While demand is strong, financing for these specialized assets still navigates a higher interest rate environment. Lenders, including major banks and debt funds, are showing a preference for sponsors with a proven track record and properties with strong tenancy and long lease terms. Bridge loans for value-add MOB plays are typically priced around SOFR + 350-550 bps, while stabilized, core MOB assets might see agency or CMBS debt at spreads of T + 175-275 bps, depending on LTV and DSCR. Life sciences development, with its higher speculative risk profile, often relies on a more complex capital stack, involving significant equity and sometimes mezzanine debt pricing in the 14-18% range.
The RadCRE Perspective
Majid Radaei, Founder of RAD Commercial Realty, notes, "The resilience of life sciences and medical office buildings isn't just about demographics; it's about essential services and innovation that cannot be easily disrupted by economic cycles or e-commerce trends. Lenders and investors are now more granular in their underwriting, scrutinizing tenant credit, lease structures, and the functional obsolescence of older facilities. We're seeing robust demand for both new, purpose-built facilities that meet stringent lab requirements and well-located MOBs within growing healthcare networks. The perceived stability of these cash flows offers a compelling counter-cyclical hedge, making them prime targets for institutional capital even when broader markets face headwinds."
RadCRE's team of specialists across various asset classes provides expert advisory services in the acquisition, disposition, and financing of these complex properties, leveraging our deep market insights and financial modeling capabilities to structure optimal transactions for our clients. Whether it's sourcing advantageous financing for a cutting-edge lab facility or identifying value-add MOB opportunities, RadCRE assists clients in navigating this dynamic sector.
Tags: life sciences real estate, medical office building investment, CRE capital markets, healthcare real estate, commercial real estate financing
Sources: CBRE Research, Real Capital Analytics (RCA), CoStar, Ventas Press Releases